Results 121 to 130 of about 1,270 (136)
FEBS Journal, 2020 Organic anion-transporting polypeptide 1A2 (OATP1A2), expressed in the human blood-brain barrier, promotes drug uptake from the blood and hence can be exploited for central nervous system-targeted drug delivery. The thyroid transporter OATP1C1, expressed
Gergely SzakÁCs +2 more
exaly +2 more sources
OATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor Agonists and Antagonists
Molecular Pharmaceutics, 2020 Interaction with the dopaminergic system in the central nervous system is either therapeutically intended or it is a side effect. In both cases, dopamine-receptor agonists (DRA) like the ergoline derivative bromocriptine and dopamine-receptor antagonists
Stefan Oswald +2 more
exaly +2 more sources
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2
Clinical Pharmacology and Therapeutics, 2011 The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found that imatinib is transported by the intestinal uptake carrier organic anion transporting ...
R H J Mathijssen +2 more
exaly +2 more sources
Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2 [PDF]
AAPS Journal, 2013 The solute carrier organic anion transporting polypeptide 1A2 (OATP1A2, SLCO1A2) is implicated in the cellular influx of a number of drugs. We identified five novel single nucleotide polymorphisms (SNPs) in coding exons of the SLCO1A2 gene in a cohort of
Zhou F, Michael Murray, W Bret Church
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
PI-50OATP1A2 is the major uptake transporter of fexofenadine in humans
Clinical Pharmacology and Therapeutics, 2006Richard Kim, David Bailey
exaly